For Healthcare Professionals - United States

TAVR

Transcatheter Aortic Valve Replacement

CoreValve Evolut R US Study 30-Day Results

Advancing TAVR Therapy

Excellent Procedural Results with a Strong Safety Profile

The Evolut R US study enrolled 241 high and extreme risk patients across 23 US sites. Study outcomes show how Evolut R advances TAVR therapy.

Chart

Exceptional 30-Day Outcomes

Chart

Unsurpassed Hemodynamic Performance

Single-Digit Gradients

Chart

Low Rate of Moderate and No Severe PVL

Chart